Crinetics Pharmaceuticals, Inc. (CRNX): Price and Financial Metrics
Crinetics Pharmaceuticals, Inc. (CRNX)
Today's Latest Price: $12.08 USD
Updated Oct 30 4:00pm
Add CRNX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
CRNX Stock Summary
- Crinetics Pharmaceuticals Inc's stock had its IPO on July 18, 2018, making it an older stock than only 5.26% of US equities in our set.
- With a price/sales ratio of 442.85, Crinetics Pharmaceuticals Inc has a higher such ratio than 99% of stocks in our set.
- Revenue growth over the past 12 months for Crinetics Pharmaceuticals Inc comes in at -47.11%, a number that bests just 4.85% of the US stocks we're tracking.
- Stocks that are quantitatively similar to CRNX, based on their financial statements, market capitalization, and price volatility, are QURE, AUTL, OTIC, RCUS, and SYRS.
- CRNX's SEC filings can be seen here. And to visit Crinetics Pharmaceuticals Inc's official web site, go to www.crinetics.com.
CRNX Stock Price Chart Interactive Chart >
CRNX Price/Volume Stats
| Current price | $12.08 | 52-week high | $26.67 |
| Prev. close | $12.48 | 52-week low | $10.63 |
| Day low | $11.70 | Volume | 177,600 |
| Day high | $12.58 | Avg. volume | 142,373 |
| 50-day MA | $15.14 | Dividend yield | N/A |
| 200-day MA | $16.87 | Market Cap | 397.24M |
Crinetics Pharmaceuticals, Inc. (CRNX) Company Bio
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is based in San Diego, California.
Loading social stream, please wait...